Condition
Antibodies Drug Specific
Total Trials
2
Recruiting
0
Active
0
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Treatment Research
2 treatments under study, led by Tinidazole
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 2 trials
Success Rate
100.0%
+13.4% vs benchmark
Late-Stage Pipeline
50%
1 trials in Phase 3/4
Results Transparency
0%
0 of 2 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
1Total
Phase 4 (1)
Trial Status
Completed2
Trial Success Rate
100.0%
Benchmark: 86.6%
Based on 2 completed trials
Clinical Trials (2)
Research Network
Common Treatments
- Tinidazole1
- Zymutest Hia Immunoglobulin G Elisa Enzymelinked Immunosorbent Assay1
Active Sponsors
- Medical University of Vienna1
- Shanghai Children's Hospital1
- Tongji Hospital1
Top Investigators
Tongji Hospital
Department of Anaesthesia, Intensive Care Medicine and Pain Medicine, Medical University of Vienna
Related Conditions
- Cholangitis Secondary Biliary1
- Treatment Compliance1
- Thrombocytopenia1